Susan Kearney
Overview
Explore the profile of Susan Kearney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wickramasinghe S, Hettiarachchi S, Kearney S, Gudur S
Respirol Case Rep
. 2025 Feb;
13(2):e70123.
PMID: 39975978
Encysted pneumomediastinum with septations is an extremely rare phenomenon. Talc treatment can leak through fistulous tracts to the mediastinum, walling off air collection, which is not commonly described in the...
2.
Berntorp E, LeBeau P, Ragni M, Borhany M, Abajas Y, Tarantino M, et al.
Haemophilia
. 2022 Mar;
28(3):453-461.
PMID: 35263495
Introduction: The B-Natural study is a multicentre, multinational, observational study of haemophilia B (HB) designed to increase understanding of clinical manifestations, treatment and quality of life (QoL). Aim: To characterise...
3.
Astermark J, Holstein K, Abajas Y, Kearney S, Croteau S, Liesner R, et al.
Haemophilia
. 2021 Jun;
27(5):802-813.
PMID: 34118102
Introduction: Inhibitors develop less frequently in haemophilia B (HB) than haemophilia A (HA). However, when present, the success of tolerization by immune tolerance induction (ITI) therapy is lower and the...
4.
Shapiro A, Ragni M, Borhany M, Abajas Y, Tarantino M, Holstein K, et al.
Haemophilia
. 2020 Dec;
27(1):49-59.
PMID: 33278853
Introduction: Haemophilia B (HB) is less well studied than haemophilia A (HA); despite similarities between the two inherited bleeding disorders, important differences remain that require further research. Aim: B-Natural is...
5.
Trakymiene S, Economou M, Kenet G, Landorph A, Shen C, Kearney S
J Thromb Haemost
. 2020 Sep;
18 Suppl 1:15-25.
PMID: 32940955
Background: N8-GP (turoctocog alfa pegol; Esperoct , Novo Nordisk A/S, Bagsvaerd, Denmark) is a glycoPEGylated, extended half-life human recombinant factor VIII (FVIII). Objective: Here, we report end-of-trial safety and efficacy...
6.
Carcao M, Kearney S, Lu M, Taki M, Rubens D, Shen C, et al.
Thromb Haemost
. 2020 May;
120(5):737-746.
PMID: 32369845
Long-term safety and efficacy data of extended half-life factor IX (FIX) prophylaxis in children with hemophilia B (HB) are sparse. paradigm 5 is a multinational, open-label, single-arm, phase III trial...
7.
Buranahirun C, Walsh K, Mrakotsky C, Croteau S, Rajpurkar M, Kearney S, et al.
Pediatr Blood Cancer
. 2019 Oct;
67(1):e28004.
PMID: 31595670
Almost all of what is known about neurologic and cognitive development in hemophilia derives from the Hemophilia Growth and Development Study, conducted during an era when treatment regimens and comorbidities...
8.
Escher P, Tu A, Kearney S, Wheelwright M, Petronio J, Kebriaei M, et al.
Childs Nerv Syst
. 2019 Jun;
35(8):1357-1362.
PMID: 31147744
Purpose: To assess the success of a protocol using preoperative erythropoietin (EPO) and iron with perioperative tranexamic acid (TXA) in reducing blood transfusion in sagittal craniosynostosis surgery. Methods: A retrospective...
9.
Kearney S, Raffini L, Pham T, Lee X, von Mackensen S, Landorph A, et al.
Patient Prefer Adherence
. 2019 May;
13:497-513.
PMID: 31040652
Background: Prophylactic treatment regimens lead to improvements in health-related quality-of-life (HRQoL) among individuals with hemophilia. Turoctocog alfa pegol (N8-GP) provides the benefit of extending the duration of protection from bleeding...
10.
Curry N, Albayrak C, Escobar M, Holme P, Kearney S, Klamroth R, et al.
Haemophilia
. 2019 Mar;
25(3):373-381.
PMID: 30817066
Introduction: Turoctocog alfa pegol (N8-GP) is a site-specific, 40 kDa glycoPEGylated recombinant factor VIII (FVIII) product with an extended half-life. The comprehensive main phase of the pivotal pathfinder 2 trial...